China Bridge Consulting examines the opportunities and challenges ahead for China’s mRNA vaccine industry in the post-COVID era. Having eschewed foreign-made mRNA products from Pfizer/BioNTech and Moderna during the peak of the pandemic in the hope of securing domestic alternatives, China and its sizeable biopharma industry now face a challenging path…
China Vaccinating the elderly has been a key factor in ensuring protection against fatality during COVID-19, writes Bridge Consulting’s Stefania Jiang. However, the experience of it in China has been one of ups and downs as vaccine hesitancy and a slew of social issues have greatly affected uptake. But ultimately, this…
Global PharmaBoardroom’s network of thought leaders continued to provide some of our top content in 2022, covering topics such as Africa’s first integrated drug discovery platform, Chinese vaccine exports, inequities in US healthcare, antimicrobial pollution and new pharmaceutical legislation in Europe. See our dedicated op-ed page for all of the year’s contributions…
See our Cookie Privacy Policy Here
